2024
Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial
Jacobs J, Booth G, Stephens L, Tormey C, Adkins B. Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial. The Lancet 2024, 404: 433. PMID: 39097393, DOI: 10.1016/s0140-6736(24)01264-9.Peer-Reviewed Original Research
2022
Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients
Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O’Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA, Rahman F, Ajayi A, Rodriguez S, Ledesma A, Keeling D, Rappoport N, Ebel S, Kim J, Chang M, Chan K, Patel P, Martocci A, Dave S, Darwish Y, Taveras M, Shoyelu V, Xin P, Iturrate E, Moldolsky L, Raimondo B, Mendez S, Hughes P, Sterling S, Lord A, Yaghi S, Veloso K, Sheikh M, Visconti-Ferrara E, Fleming A, Youn H, Jane Fran B, Medina R, McKell R, Khan S, Hamilton T, Sanchez C, Patel N, Cleare L, Vergnolle O, Nakouzi A, Quevedo G, Bortz R, Wirchnianski A, Florez C, Babb R, Ayala J, Tsagaris K, James A, Eke I, Obeidallah A, Sandu O, Sohval S, Serrano-Rahman L, Uehlinger J, Bartash R, Al-Abduladheem A, Gendlina I, Sheridan C, Bortnick A, Eichler J, Kaufman R, Yukelis S, Pennock M, Goggin M, Shen C, Annam J, Khokhar A, Barboto D, Lally B, Lee A, Lee M, Yang X, Allen S, Malaviya A, Moussa O, Park R, Sample R, Bae A, Benoni G, Boerger L, Baker L, Luther M, Ameti L, Briggs N, Golden M, Gormally M, Huang G, Johnson R, Morrison A, Montagna-Hill M, Rivera B, Cortezzo G, Debski K, Nicoletti, DeBenedictis K, Davis R, Marshall C, Duque Cuartas M, Beauchamps L, Bertran-Lopez J, Gonzales Zamora J, Delgado-Lelievre M, Dominguez S, Lee C, Kusack H, Karakeshishyan V, Hajaz A, Deniz D, Garcia G, Dae K, Blenet P, Jaffe D, Olson L, Sabogal D, Blust O, Del Prete Perez V, Bornia C, Rodriguez-Perez V, Calderon V, Ramdev R, Jolly A, Guzman I, Guerra R, Brito S, Hobbs R, Denham R, Dick J, Hernandez M, Nielsen L, Anjum S, Mader S, Stutz T, Mammadova M, Nichols P, Khan T, Boktour M, Castaneda B, Benitez B, Hinojosa E, Guerra B, Ortiz A, Hebbeler-Clark R, McShane P, Hibbard R, Hawkins B, Dohanich E, Wadle C, Greenlee K, Brooks J, Herrick C, Gode A, Bergl P, Hu K, Patel J, Srinivasan S, Graf J, Klis C, Reimer K, Carpenter E, Naczek C, Petersen R, Dex R, Drossart J, Zelten J, Brummitt C, Liang M, Yanny L, Dennison G, Runningen P, Brzezinski B, Fiebig S, Naczek C, Kasdorf M, Parameswaran L, Corcoran A, Rohatgi A, Wronska M, Wu X, Srinivasan R, Deng F, Filardo T, Pendse J, Blaser S, Whyte O, Gallagher J, Thomas O, Ramos D, Sturm-Reganato C, Fong C, Daus I, Payoen A, Chiofolo J, Friedman M, Wu D, Jacobson J, Schneider J, Sarwar U, Wang H, Huebinger R, Dronavalli G, Bai Y, Grimes C, Eldin K, Umana V, Martin J, Heath T, Bello F, Ransford D, Laurent-Rolle M, Shenoi S, Akide-Ndunge O, Thapa B, Peterson J, Knauf K, Patel S, Cheney L, Tormey C, Hendrickson J. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. JAMA Internal Medicine 2022, 182: 115-126. PMID: 34901997, PMCID: PMC8669605, DOI: 10.1001/jamainternmed.2021.6850.Peer-Reviewed Original ResearchConceptsCCP recipientsPlacebo recipientsSecondary outcomesSymptom durationHospitalized patientsPrimary outcomeDay 28COVID-19SARS-CoV-2 serostatusSARS-CoV-2 titersWorld Health Organization (WHO) ordinal scaleCOVID-19 convalescent plasmaConvalescent plasma usePlacebo-controlled trialLess daysExploratory subgroup analysisNon-Hispanic blacksSARS-CoV-2CCP efficacyConcomitant medicationsAdverse eventsClinical improvementSymptom onsetConvalescent plasmaMedian age
2021
Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19
Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng Y, Hendrickson JE, Tormey CA, Desruisseaux MS. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLOS ONE 2021, 16: e0254453. PMID: 34320004, PMCID: PMC8318280, DOI: 10.1371/journal.pone.0254453.Peer-Reviewed Original ResearchConceptsCOVID-19 convalescent plasmaSevere COVID-19Convalescent plasmaPlasma recipientsHospital mortalityUnexposed cohortCCP administrationSevere COVID-19 infectionPropensity score-matched analysisCOVID-19Limited therapeutic optionsCOVID-19 infectionCoronavirus disease 2019CCP recipientsHospital stayPrimary endpointSecondary endpointsHospital daysHospital dischargeEarly administrationComplete followMechanical ventilationTherapeutic optionsClinical differencesSevere disease
2018
A Cluster of Cases of Babesia microti Among Neonates Traced to a Single Unit of Donor Blood
Glanternik JR, Baine IL, Rychalsky MR, Tormey CA, Shapiro ED, Baltimore RS. A Cluster of Cases of Babesia microti Among Neonates Traced to a Single Unit of Donor Blood. The Pediatric Infectious Disease Journal 2018, 37: 269-271. PMID: 28945680, DOI: 10.1097/inf.0000000000001803.Peer-Reviewed Original ResearchConceptsNeonatal intensive care unitHigh-grade parasitemiaTransfusion-transmitted babesiosisIntensive care unitCluster of casesBlood transfusionPremature infantsCare unitExchange transfusionDonor bloodInfantsBabesia microtiTransfusionBabesiosisNeonatesParasitemiaAzithromycinCliniciansAtovaquoneSingle unitBlood
2016
Successful Use of Four Factor-Prothrombin Complex Concentrate for Congenital Factor X Deficiency in the Setting of Neurosurgery
Siddon AJ, Tormey CA. Successful Use of Four Factor-Prothrombin Complex Concentrate for Congenital Factor X Deficiency in the Setting of Neurosurgery. Lab Medicine 2016, 47: e35-e37. PMID: 27378481, PMCID: PMC4985779, DOI: 10.1093/labmed/lmw037.Peer-Reviewed Original ResearchConceptsCongenital factor X deficiencyFactor X deficiencyX deficiencyExcessive bleedingComplex concentrateFour-factor prothrombin complex concentrateFactor prothrombin complex concentrateFirst-line therapyAnterior cervical discectomySetting of traumaProthrombin complex concentrateFresh frozen plasmaRare coagulation disorderMajor neurosurgeryCervical discectomyThromboembolic complicationsSpontaneous hemorrhageCoagulation disordersFrozen plasmaInvasive proceduresOperative casesBleedingWhite menDeficiencyDisorders
2015
Novel Oral Anticoagulants: Efficacy, Laboratory Measurement, and Approaches to Emergent Reversal
Gehrie E, Tormey C. Novel Oral Anticoagulants: Efficacy, Laboratory Measurement, and Approaches to Emergent Reversal. Archives Of Pathology & Laboratory Medicine 2015, 139: 687-92. PMID: 25927153, DOI: 10.5858/arpa.2013-0677-rs.Peer-Reviewed Original ResearchConceptsNovel oral anticoagulantsManagement of NOACOral direct thrombin inhibitorDirect factor Xa inhibitorVitamin K antagonistsDirect thrombin inhibitorFactor Xa inhibitorsCertain clinical circumstancesOral anticoagulationWarfarin effectivenessK antagonistsOral anticoagulantsClinical efficacySafety profileEmergent reversalClinical circumstancesXa inhibitorsUS FoodDrug AdministrationThrombin inhibitorsNew drugsDrugsEfficacyInhibitorsLaboratory assays
2013
Limiting the Extent of a Delayed Hemolytic Transfusion Reaction With Automated Red Blood Cell Exchange
Tormey CA, Stack G. Limiting the Extent of a Delayed Hemolytic Transfusion Reaction With Automated Red Blood Cell Exchange. Archives Of Pathology & Laboratory Medicine 2013, 137: 861-4. PMID: 23721278, DOI: 10.5858/arpa.2012-0154-cr.Peer-Reviewed Original ResearchConceptsRed blood cell exchangeHemolytic transfusion reactionsDAT resultsTransfusion reactionsDirect antiglobulin test resultsCell exchangeIncompatible red blood cellsSymptoms of hemolysisRed blood cell unitsPositive antibody screenBlood group antibodiesAntigen-negative unitsAnamnestic increaseAntigen reexposureFurther hemolysisRed blood cellsAntibody screenGroup antibodiesPatient historyBlood cellsDHTRTransfusionHemolysisSymptomsCell units
2008
Adult nesidioblastosis. Clinicopathologic correlation between pre-operative selective arterial calcium stimulation studies and post-operative pathologic findings.
Kenney B, Tormey CA, Qin L, Sosa JA, Jain D, Neto A. Adult nesidioblastosis. Clinicopathologic correlation between pre-operative selective arterial calcium stimulation studies and post-operative pathologic findings. JOP Journal Of The Pancreas 2008, 9: 504-11. PMID: 18648143.Peer-Reviewed Original ResearchConceptsDifferential diagnosisDiffuse islet cell hyperplasiaPost-operative pathologic findingsMarked insulin releaseSevere hyperinsulinemic hypoglycemiaIslet cell hyperplasiaCase of nesidioblastosisIslet cell proliferationPancreatic ductal epitheliumRoutine diagnostic laboratoryFactitious hypoglycemiaRadiological findingsSevere hypoglycemiaSubtotal pancreatectomyPathologic findingsAdult nesidioblastosisCell hyperplasiaClinicopathologic correlationPancreatic segmentsDuctal epitheliumHyperinsulinemic hypoglycemiaCalcium challengeHistologic examinationLaboratory examinationsPartial pancreatectomy